Enalare Therapeutics
Princeton, US · Founded 2018 · Delaware corporation
Biotech
Founders & leadership
GS
Gino SantiniDirector
JP
Joseph PergolizziExecutive Officer, Director
HC
Herman CukierExecutive Officer, Director
JP
Joseph PetkoDirector
DM
Daniel MottoExecutive Officer
RY
Robert YedidDirector
Reported raises · per SEC filings
Form D private placements▶$12.5MraisedAug 2022 · 1 investors · PharmaceuticalsRule 506(b)
▶$12.5MraisedAug 2022 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert YedidDirector
- Mark ColemanDirector
- Daniel MottoExecutive Officer
- Joseph PergolizziExecutive Officer, Director
- Gino SantiniDirector
- Joseph PetkoDirector
- Herman CukierExecutive Officer, Director
- Offering amount
- $55M
- Amount sold
- $12.5M
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$1MraisedFeb 2022 · 12 investors · PharmaceuticalsRule 506(b)
▶$1MraisedFeb 2022 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gino SantiniDirector
- Daniel MottoExecutive Officer
- Robert YedidDirector
- Mark ColemanDirector
- Joseph PergolizziExecutive Officer, Director
- Herman CukierExecutive Officer, Director
- Joseph PetkoDirector
- Offering amount
- $10M
- Amount sold
- $1M
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$10MofferedDec 2020 · PharmaceuticalsRule 506(b)
▶$10MofferedDec 2020 · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gino SantiniDirector
- Joseph PergolizziExecutive Officer, Director
- Herman CukierExecutive Officer, Director
- Joseph PetkoDirector
- Daniel MottoExecutive Officer
- Robert YedidDirector
- Offering amount
- $10M
- Proceeds to insiders
- $1.4M
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $319.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.